HCV induces hepatocellular carcinoma in infected individuals; our findings in this study as well as others [13], [15], [24] that inhibition of MEK signaling leads to the up-regulation of HCV replication raise concerns about the potential use of those inhibitors for the treatment of cancer in HCV-infected individuals. Here, MAP2K7 is linked to hepatocellular carcinoma.